Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

Zealthy and Ro both offer FDA-approved, generic GLP-1s at personalized dosages to fit your needs. These platforms also have a ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

At medical conferences and hospital cafeterias, one thing has become increasingly clear—many doctors are using Ozempic, ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who’ve ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.